Extended wearing trial of Trifield lens device for 'tunnel vision'.
Severe visual field constriction (tunnel vision) impairs the ability to navigate and walk safely. We evaluated Trifield glasses as a mobility rehabilitation device for tunnel vision in an extended wearing trial. Twelve patients with tunnel vision (5-22 degrees wide) due to retinitis pigmentosa or choroideremia participated in the 5-visit wearing trial. To expand the horizontal visual field, one spectacle lens was fitted with two apex-to-apex prisms that vertically bisected the pupil on primary gaze. This provides visual field expansion at the expense of visual confusion (two objects with the same visual direction). Patients were asked to wear these spectacles as much as possible for the duration of the wearing trial (median 8, range 6-60 weeks). Clinical success (continued wear, indicating perceived overall benefit), visual field expansion, perceived direction and perceived visual ability were measured. Of 12 patients, nine chose to continue wearing the Trifield glasses at the end of the wearing trial. Of those nine patients, at long-term follow-up (35-78 weeks), three reported still wearing the Trifield glasses. Visual field expansion (median 18, range 9-38 degrees) was demonstrated for all patients. No patient demonstrated adaptation to the change in visual direction produced by the Trifield glasses (prisms). For reported difficulty with obstacles, some differences between successful and non-successful wearers were found. Trifield glasses provided reported benefits in obstacle avoidance to 7 of the 12 patients completing the wearing trial. Crowded environments were particularly difficult for most wearers. Possible reasons for long-term discontinuation and lack of adaptation to perceived direction are discussed.
Woods
Russell L
RL
Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114-2500, USA. russell.woods@schepens.harvard.edu
Giorgi
Robert G
RG
Berson
Eliot L
EL
Peli
Eli
E
D000328:Adult; D015794:Choroideremia / Q000150:complications / Q000534:rehabilitation*; D005139:Eyeglasses; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D051346:Mobility Limitation; D012174:Retinitis Pigmentosa / Q000150:complications / Q000534:rehabilitation*; D011795:Surveys and Questionnaires; D013997:Time Factors; D014786:Vision Disorders / Q000209:etiology / Q000628:therapy*; D014794:Visual Fields
Am J Optom Physiol Opt. 1985 Feb;62(2):142-8
3985103
N Engl J Med. 1997 Oct 30;337(18):1279-84
9345078
Age Ageing. 2003 Nov;32(6):619-25
14600003
Optom Vis Sci. 2001 May;78(5):304-15
11384008
J Am Geriatr Soc. 2001 May;49(5):508-15
11380741
Optom Vis Sci. 1991 Sep;68(9):728-37
1745500
J Epidemiol Community Health. 2002 Aug;56(8):631-6
12118057
J Am Geriatr Soc. 1989 Jun;37(6):495-500
2715555
Optom Vis Sci. 2001 Sep;78(9):657-66
11587200
Invest Ophthalmol Vis Sci. 1999 Apr;40(5):865-77
10102283
Optom Vis Sci. 2005 Nov;82(11):946-54
16317369
J Exp Psychol. 1969 Apr;80(1):125-32
5787407
Am J Optom Physiol Opt. 1976 Sep;53(9 Pt 1):464-7
984175
ACM Trans Appl Percept. 2007 Jan;4(1):8
18167511
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4445-50
17898264
J Vis. 2008 Dec 22;8(14):25.1-8
19146326
J Rehabil Res Dev. 2004 May;41(3A):337-46
15543450
Ophthalmic Physiol Opt. 1993 Apr;13(2):143-50
8265148
Aging Clin Exp Res. 2004 Oct;16(5):382-8
15636464
Aust J Public Health. 1993 Sep;17(3):240-5
8286498
J Am Optom Assoc. 1993 Jan;64(1):60-70
8454830
Age Ageing. 2000 Sep;29(5):441-6
11108417
Arch Ophthalmol. 2001 Jul;119(7):1050-8
11448327
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5295-302
17122116
Arch Ophthalmol. 2008 May;126(5):657-64
18474776
Optom Vis Sci. 2002 Sep;79(9):569-80
12322927
Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4152-9
16936136
Optom Vis Sci. 2002 Nov;79(11):715-23
12462540
Optom Vis Sci. 2009 May;86(5):492-502
19357552
Invest Ophthalmol Vis Sci. 1993 Jan;34(1):120-9
8425819
Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4509-15
19458339
Optom Vis Sci. 1998 Mar;75(3):174-82
9547798
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):2955-60
15326107
Invest Ophthalmol Vis Sci. 1999 Nov;40(12):2803-9
10549639
Am J Ophthalmol. 2007 Aug;144(2):209-216
17533108
Cochrane Database Syst Rev. 2010 May 12;(5):CD003925
20464725
Arch Ophthalmol. 1984 Aug;102(8):1182-4
6466183
Invest Ophthalmol Vis Sci. 1991 Feb;32(2):422-32
1993595
Optom Vis Sci. 2000 Sep;77(9):453-64
11014672
Lancet. 2006 Nov 18;368(9549):1795-809
17113430
Am J Optom Physiol Opt. 1982 May;59(5):413-26
7102800
Optom Vis Sci. 1998 Jul;75(7):518-24
9703041
Can J Ophthalmol. 2006 Feb;41(1):27-33
16462868
J Soc Inf Disp. 2007 Dec;15(12):1037-1045
18172511
Optom Vis Sci. 2001 Sep;78(9):667-75
11587201
Percept Psychophys. 1993 Aug;54(2):195-204
8361835
Stat Med. 1997 Nov 30;16(22):2529-42
9403954
Invest Ophthalmol Vis Sci. 1993 Apr;34(5):1659-76
8473105
Optom Vis Sci. 1996 Oct;73(10):621-37
8916133